Publications by authors named "MacDonald-Berko M"
Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.
Int J Chron Obstruct Pulmon Dis
August 2023
Article Synopsis
- Ensifentrine is a unique inhaled treatment that inhibits PDE3 and PDE4, helping with airway inflammation, bronchodilation, and ciliary function.
- In Phase 2 studies for COPD patients, it showed significant improvements in lung function, symptoms, and overall health quality, either alone or with other treatments.
- Currently, ensifentrine is in advanced clinical trials aimed at maintaining treatment for COPD patients, with this review focusing on its non-clinical and Phase 1 and 2 data on effectiveness and safety.
: Fractional exhaled nitric oxide (FeNO) is a valuable tool for assessing Th2 inflammation in children with asthma. Exhalation times of 6 and 10 s meet the current recommendations for assessing FeNO. The 6-s exhalation provides an alternative for 7-10 year olds not able to complete the 10-s exhalation.
View Article and Find Full Text PDF